Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 11/16/2018 9:25:53 AM - Followers: 155 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#7619  Sticky Note https://seekingalpha.com/article/4222803 Lunacy aka John Galt 11/16/18 09:25:53 AM
#7619   https://seekingalpha.com/article/4222803 Lunacy aka John Galt 11/16/18 09:25:53 AM
#7618   Juan Manuel Mejía (@Meyaix) 11/15/18, 12:37 AM Finally out... AURA-LV biotech_researcher 11/15/18 06:38:43 PM
#7616   50% of my Roth is invested in AUPH. Newbie1421 11/15/18 12:29:11 PM
#7615   83,659 share block after hours at $5.16. heldnova 11/14/18 06:00:39 PM
#7614   DES trial enrollment complete with 100 patients. Lunacy aka John Galt 11/14/18 12:49:33 PM
#7613   Bought another 10,000 shares today at $5.15. heldnova 11/14/18 11:07:18 AM
#7612   At the Jefferies London conference 2018... Jesspro 11/14/18 07:36:05 AM
#7611   Another fine day in the stock market and Maciste 11/12/18 03:56:46 PM
#7610   He always goes for the jugular so it’s Jesspro 11/10/18 08:58:55 PM
#7609   Yes AUPH is way more than $24 puravida 11/10/18 07:57:25 PM
#7608   No real chance auph goes after Denner. tiv111 11/10/18 03:16:19 PM
#7607   Imagine Denner selling a strong drug Jesspro 11/10/18 10:00:42 AM
#7606   I agree Denner not the right pick to puravida 11/09/18 06:50:49 PM
#7605   As I former Ariad shareholder, I'd be right rumrunner528 11/09/18 03:54:40 PM
#7604   That’s Funny! Hotrodder1 11/09/18 03:47:48 PM
#7603   I wish I had a dollar for every Maciste 11/09/18 01:25:42 PM
#7602   Buying opportunity and thanks. ScifiSailor 11/09/18 09:58:10 AM
#7601   Thanks, I respect your opinion. Apparently, the early Jesspro 11/09/18 09:41:18 AM
#7600   Hey Jess. Not one of the ARIAD crew. ScifiSailor 11/09/18 09:33:25 AM
#7599   Sci-fi, were you an Ariad investor before? If Jesspro 11/09/18 08:57:10 AM
#7598   Deal maker skills not primary CEO criteria, based ScifiSailor 11/09/18 08:33:58 AM
#7597   The chances of Voclosporin success in the P3 Jesspro 11/09/18 07:40:03 AM
#7596   He provided the reason for retirement on the northern vortex 11/09/18 06:36:43 AM
#7595   Possibly non-event until we see who the replacement Lunacy aka John Galt 11/09/18 12:19:02 AM
#7594   Do you think it is perceived by the Jesspro 11/09/18 12:07:48 AM
#7593   Makes a lot of sense to me. Lunacy aka John Galt 11/08/18 11:45:08 PM
#7592   Could he be sick? Could auph have Jesspro 11/08/18 10:35:37 PM
#7591   FromReuters.... Jesspro 11/08/18 10:28:45 PM
#7590   SEC filing form 6-k Maciste 11/08/18 04:28:15 PM
#7589   I'll bite. Where are you getting this. Newbie1421 11/08/18 04:26:42 PM
#7588   I'm surprised to hear that Mr. Glickman is Maciste 11/08/18 04:16:54 PM
#7587   Moose, 7 weeks between now and EOY for Jesspro 11/08/18 10:49:14 AM
#7586   Thanks nferna! Favorite son.. biotech_researcher 11/04/18 07:42:28 AM
#7585   nice I hadn't heard. thanks for sharing. Immuno-Oncology puravida 11/03/18 04:24:09 PM
#7584   Nferna, It’s not public yet but the write Jesspro 11/02/18 06:53:39 PM
#7583   Speaking of Clackson, in case you haven't heard: http://akrevia.com/#team nferna 11/02/18 04:29:59 PM
#7582   BR is bullish? wow. ;) I puravida 11/01/18 05:43:31 PM
#7581   Pura, last time we heard from Vid he Jesspro 11/01/18 04:30:05 PM
#7580   Good question, what became of Vid? rumrunner528 11/01/18 03:33:35 PM
#7579   its been a minute, nice to see so puravida 10/31/18 08:22:25 AM
#7578   It is possible.it seems like kzr is on Jesspro 10/31/18 06:54:25 AM
#7577   Anyone know if KZR maybe the problem for lidopete 10/31/18 03:51:58 AM
#7576   This market is out of control. Maciste 10/24/18 11:04:55 AM
#7575   Why? If VOS crashes and burns and nferna 10/24/18 07:02:37 AM
#7574   Jess, that's a good point. ScifiSailor 10/23/18 03:31:59 PM
#7573   I REALLY fear $4’s......:^{ biotech_researcher 10/23/18 11:03:44 AM
#7572   Only if the results are stellar. What if Jesspro 10/22/18 12:33:26 PM
#7571   Just brutal action.... biotech_researcher 10/22/18 10:36:57 AM
#7570   Yes, DES will trigger the upside move.. Then biotech_researcher 10/21/18 07:12:43 PM
#7569   AUPH will follow general biotech (IBB, XBI for ScifiSailor 10/21/18 06:05:16 PM